Forte Biosciences (FBRX) Other Non-Current Liabilities (2016 - 2026)
Forte Biosciences (FBRX) reported Other Non-Current Liabilities of $1.5 million for Q1 2026, up 42.33% quarter-over-quarter from $1.0 million in Q4 2025.
Forte Biosciences (FBRX) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 5 years of Other Non-Current Liabilities data on file, last reported at $1.5 million in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $1.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (changed N/A YoY), and the FY2025 annual result was $1.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities rose to $1.5 million in Q1 2026 per FBRX's latest filing, from $1.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.5 million in Q1 2026 and troughed at $1.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | 1.04 Mn |
| Dec 31, 2019 | 81,000.00 |
| Sep 30, 2019 | 81,000.00 |
| Mar 31, 2017 | 67,000.00 |
| Dec 31, 2016 | 126,000.00 |